VolitionRx Reports 112% H1 2026 Revenue Growth to $1.4 Million
VolitionRx Limited said first-half 2026 revenue rose 112% to $1.4 million, driven by progress in sepsis detection, cancer diagnostics, and veterinary tests. The broader market commentary included bitcoin trading near $79,900 and approaching $80,500 resistance, plus Ethereum Layer 2 networks processing nearly 30 million daily transactions and Polymarket introducing leveraged perpetual futures up to 20x.